Form 4: Revvity Executive Tajinder S. Vohra Executes Stock Option and Sells Shares

Tajinder S. Vohra, a Senior Vice President at Revvity, Inc., exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On February 27, 2024, Tajinder S. Vohra, a Senior Vice President at Revvity, Inc., exercised a non-qualified stock option to acquire 7,918 shares of common stock at a price of $54.565 per share.
• Vohra then sold 2,652 shares at a weighted average price of $104.84 and 5,266 shares at a weighted average price of $105.66.
• These sales were executed under a 10b5-1 trading plan adopted on August 4, 2023.
• Following these transactions, Vohra directly owns 26,113 shares of Revvity common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the executive's view of the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are common and are often scrutinized by investors to gauge management's confidence in the company's future prospects. Sales under 10b5-1 plans are generally viewed as less informative since they are pre-arranged.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to sell shares while avoiding accusations of insider trading.
• Comparable companies in the life sciences and diagnostics industries, such as Danaher (DHR) and Thermo Fisher Scientific (TMO), also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates